Utilization of CMA in myeloid, lymphoid and plasma cell disorders

Cytogenetic diagnostic analysis has been inexorably tied to the understanding of leukemic disorders since Rowley first associated the presence of the 9;22 translocation with chronic myeloid leukemia [1]. Furthermore, karyotyping of leukemia cells has served for decades as an essential clinical tool for improved diagnosis, risk stratification and treatment selection. Diagnostic testing has progressed over the last several decades and has evolved from cytogenetic and FISH to chromosomal microarray analysis (CMA) and sequencing.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research